Last reviewed · How we verify
OPB-31121 phase2
At a glance
| Generic name | OPB-31121 phase2 |
|---|---|
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPB-31121 phase2 CI brief — competitive landscape report
- OPB-31121 phase2 updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI